Description of patient with telangiectasis and palmar erythema without any structural liver changes or changes of liver laboratory parameters due to treatment of Her -2 -positive breast cancer with Ado-Trastuzumab-Emtansine
Internal Medicine Residency Program, Sunrise Health Consortium GME, Mountain View Hospital, Las Vegas, Nevada, USA.
Case Study
World Journal of Advanced Research and Reviews, 2021, 11(02), 169–172
Article DOI: 10.30574/wjarr.2021.11.2.0373
Publication history:
Received on 08 July 2021; revised on 14 August 2021; accepted on 16 August 2021
Abstract:
Ado- Trastuzumab-Emtansine is approved by EMA and FDA for treatment of HER-2-positive metastatic breast cancer. The drug combines the cytotoxic activity of emtansine with trastuzumab [1,2,3]. Here we are describing 50- year old woman with 3-ple positive left breast cancer with metastasis to left axillary lymph nodes treated with the drug. The patient had normal liver and spleen structure on CT of the abdomen with I.V. contrast, along with a normal liver function test. However she did have a mild elevation of her indirect bilirubin after the initiation of the drug. Despite the normal liver and spleen and absence of Cirrhosis the patient developed drug induced spider angiomas on the upper chest, upper back, shoulders along with palmar erythema. The association of the Ado-Trastuzumab-Emtansine with spider angiomas and palmar erythema in those with normal liver and spleen function, with only a mild elevation of indirect bilirubin is discussed in the article [1].
Keywords:
Spider angiomas; Palmar erythema; Liver; spleen; Indirect bilirubin; Ado-trastuzumab-emtansine
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0